Close

Mizuho Boosts PT on Clovis Oncology (CLVS) to $23 Following Rucaparib NDA Approval

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. META
2. CMG
3. LRCX
4. IBM
5. SPY
6. HCP
7. BSX
8. PI
9. NOW
10. ORCL


Go back to Mizuho Boosts PT on Clovis Oncology (CLVS) to $23 Following Rucaparib NDA Approval
CLOVIS ONCOLOGY (NASDAQ: CLVS) Delayed: 0.08 --0 (-0%)
Previous Close $0.08    52 Week High $40.29 
Open $0.08    52 Week Low $11.57 
Day High $0.08    P/E N/A 
Day Low $0.08    EPS $-2.82 
Volume 75,364